University of Cape Town   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Cape Town South Africa (1829)

Organization Overview

First Clinical Trial
1993
NCT00002557
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Centre for TB Research and Innovation, UCT Lung Institute | Centre for Tuberculosis Research Innovation, University of Cape Town Lung Institute | CIDRI-Africa, University of Cape Town | Department of Medicine, University of Cape Town | East London Hospital Complex, South Africa | Effective Care Research Unit, East London Hospital Complex, South Africa | Effective Care Research Unit, Frere Maternity Hospital, East London Hospital Complex | Hatter Institute for Cardiovascular Disease in Africa | Hatter Institute for Cardiovascular Research In Africa (HICRA), University of Cape Town | Mark Hatherill | Nkanyiso Hadebe | Professor & Co-Director, University of Cape Town | Professor Karen I Barnes | Red Cross Children's Hospital, University of Cape Town | The Abdul Latif Jameel Poverty Action Lab | UCT | UCT Diabetes Clinical Trials Unit - Faculty of Health Sciences - South-Africa | UCT Lung Institute | UCT Lung Institute, Cape Town, South Africa | UCT Lung Institute, University of Cape Town | University Cape Town | University of Cape | University of Cape Town | University of Cape Town, Cape Town, South Africa | University of Cape Town, Faculty of Health Sciences | University of Cape Town, Groote Schuur Hospital | University of Cape Town Lung Institute | University of Cape Town Lung Institute (Pty) Ltd | University of Cape Town Lung Institute Pty (Ltd) | University of Cape Town Lung Institute (Pty) Ltd, South Africa | University of Cape Town South African Tuberculosis Vaccine Initiative | Wellcome Centre for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular Medicine, University of Cape Town | Wellcome Centre for Infectious Diseases Research in Africa, University of Cape Town

Active Ingredients

Drugs in Phase 4 Trials (20)

amlodipine (norvasc) (1 trial)

bacille calmette-guerin (4 trials)

coartem (5 trials)

diclofenac (voltaren) (1 trial)

dolutegravir (tivicay) (6 trials)

efavirenz (sustiva) (4 trials)

emtricitabine (emtriva) (3 trials)

etoricoxib (Gencox) (1 trial)

hydrochlorothiazide (esidrix) (1 trial)

lamivudine (epivir) (3 trials)

lopinavir (Kaletra) (4 trials)

lumefantrine (Coartem) (5 trials)

methoxyflurane (penthrane) (1 trial)

nevirapine (viramune) (2 trials)

perindopril (aceon) (1 trial)

quinine (qualaquin) (1 trial)

ritonavir (Norvir) (5 trials)

tenofovir (viread) (5 trials)

tranexamic acid (cyklokapron) (1 trial)

zidovudine (retrovir) (1 trial)

Drugs in Phase 3 Trials (49)

acetylcysteine (mucomyst) (1 trial)

acetylsalicylic acid (aspirin) (2 trials)

atorvastatin (lipitor) (1 trial)

azithromycin (zithromax) (2 trials)

bedaquiline (sirturo) (5 trials)

carvedilol (coreg) (1 trial)

chloral hydrate (1 trial)

chloroquine (1 trial)

choline (1 trial)

clofazimine (lamprene) (2 trials)

COVID-19 convalescent plasma (1 trial)

delamanid (5 trials)

dihydroartemisinin (1 trial)

ethambutol (myambutol) (9 trials)

ethionamide (trecator) (1 trial)

ferrous fumarate (1 trial)

hydralazine (apresoline) (1 trial)

hydroxychloroquine (plaquenil) (2 trials)

immuvac (1 trial)

insulin glargine (toujeo) (1 trial)

insulin glulisine (Apidra) (1 trial)

insulin human (humulin) (1 trial)

insulin lispro (humalog) (1 trial)

isoniazid (nydrazid) (16 trials)

isosorbide (isordil) (1 trial)

kanamycin (Kantrex) (1 trial)

levofloxacin (levaquin) (3 trials)

linezolid (zyvox) (5 trials)

melatonin (1 trial)

moxifloxacin (avelox) (4 trials)

mtbvac (1 trial)

nicotine (nicorette) (1 trial)

nitazoxanide (Alinia) (1 trial)

phenobarbital (Luminal) (1 trial)

piperaquine (1 trial)

prednisone (meticorten) (4 trials)

pyrazinamide (Aldinamide) (14 trials)

rifampin (17 trials)

rifapentine (priftin) (3 trials)

ringer's lactate (1 trial)

rivaroxaban (xarelto) (2 trials)

soybean oil (Intralipid) (1 trial)

sulfamethoxazole (gantanol) (1 trial)

tenofovir alafenamide (genvoya) (3 trials)

terizidone (1 trial)

trimethoprim (1 trial)

Tuberculin, Purified Protein Derivative (Tubersol) (2 trials)

vitamin d3 (1 trial)

warfarin (coumadin) (1 trial)

Drugs in Phase 2 Trials (22)

aeras-402 (1 trial)

aeras-456 (2 trials)

benzathine penicillin (1 trial)

bictegravir (Biktarvy) (1 trial)

candida albicans allergen (Candin) (1 trial)

carrageenan (1 trial)

cellulose (1 trial)

cyclophosphamide (cytoxan) (1 trial)

dexamethasone (1 trial)

doxorubicin (Doxil) (1 trial)

etoposide (vepesid) (1 trial)

human fecal microbiota (Reybota) (1 trial)

leucovorin (1 trial)

metformin (glucophage) (1 trial)

mva85a (5 trials)

naltrexone (revia) (1 trial)

opc-167832 (1 trial)

pneumococcal 13-valent conjugate vaccine (prevnar 13) (1 trial)

pretomanid (4 trials)

sq109 (1 trial)

timothy grass pollen allergen extract (Grastek) (1 trial)

vincristine (oncovin) (1 trial)

Drugs in Phase 1 Trials (6)

artefenomel (1 trial)

covidity (1 trial)

darunavir (prezista) (1 trial)

mefloquine (lariam) (1 trial)

mmv390048 (1 trial)

orm-12741 (1 trial)

Drugs in Other Trials (20)

albuterol (proventil) (1 trial)

artesunate (4 trials)

bifidobacterium infantis (1 trial)

desogestrel (Mercilon) (1 trial)

ergocalciferol (drisdol) (1 trial)

ethinyl estradiol (Estinyl) (1 trial)

glycerin (1 trial)

haloperidol (haldol) (1 trial)

immune globulin (human) (Gamastan) (1 trial)

laminaria (1 trial)

mineral oil (1 trial)

misoprostol (cytotec) (2 trials)

norgestrel (Ovral) (1 trial)

noristerat (1 trial)

petrolatum, white (Vaseline) (1 trial)

procaine benzylpenicillin (novocaine) (2 trials)

pyrimethamine (daraprim) (5 trials)

sodium chloride (1 trial)

stavudine (zerit) (1 trial)

sulfadoxine (5 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acquired Immunodeficiency Syndrome (Phase 4)

Chemical and Drug Induced Liver Injury (Phase 3)

Conjunctivitis (Phase 2)

Conjunctivitis, Allergic (Phase 2)

Coronavirus Infections (Phase 3)

Diabetes Mellitus (Phase 3)

Diabetes Mellitus, Type 1 (Phase 3)

Epilepsy (Phase 3)

Extensively Drug-Resistant Tuberculosis (Phase 3)

Fetal Alcohol Spectrum Disorders (Phase 3)

Gonorrhea (Phase 2)

Heart Diseases (Phase 3)

Heart Failure (Phase 3)

Hepatitis (Phase 3)

HIV Infections (Phase 4)

Hypersensitivity (Phase 2)

Hypertension (Phase 4)

Immune Reconstitution Inflammatory Syndrome (Phase 3)

Immunologic Deficiency Syndromes (Phase 4)

Inflammation (Phase 3)

Latent Tuberculosis (Phase 3)

Lung Diseases (Phase 3)

Lymphoma (Phase 2)

Malaria (Phase 4)

Malaria, Falciparum (Phase 1)

Malnutrition (Phase 2)

Meningitis (Phase 4)

Meningitis, Cryptococcal (Phase 4)

Multiple Chronic Conditions (Phase 2)

Mycoses (Phase 2)

Mycosis Fungoides (Phase 2)

Pericarditis (Phase 3)

Pericarditis, Tuberculous (Phase 3)

Reperfusion Injury (Phase 3)

Rheumatic Diseases (Phase 3)

Rheumatic Heart Disease (Phase 3)

Severe Acute Malnutrition (Phase 2)

Severe Acute Respiratory Syndrome (Phase 3)

Sprains and Strains (Phase 4)

Status Epilepticus (Phase 3)

Syndrome (Phase 3)

Syphilis (Phase 2)

Trichomonas Vaginitis (Phase 2)

Tuberculosis (Phase 4)

Tuberculosis, Meningeal (Phase 2)

Tuberculosis, Multidrug-Resistant (Phase 3)

Tuberculosis, Pulmonary (Phase 3)

Vaginitis (Phase 2)

Ventricular Dysfunction (Phase 3)

Ventricular Dysfunction, Left (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 108
  • # of Trial APIs: 117